Alkeran IV Side Effects
Please note - some side effects for Alkeran IV may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Side Effects by Body System - for Healthcare Professionals
Applies to: intravenous powder for injection; oral tablet
Hematologic side effects including bone marrow suppression and anemia have been reported. Bone marrow suppression is the most common and the most significant toxicity associated with melphalan in most patients. Hemolytic anemia has also been reported.
Bone marrow suppression is usually reversible if melphalan is withdrawn early enough.
Oncologic side effects including secondary malignancies such as acute nonlymphocytic leukemia, myeloproliferative syndrome, and carcinoma have been reported. Melphalan has been reported to cause chromatid or chromosome damage in humans.
The risk of leukemogenesis increases with chronicity of treatment and with cumulative dose.
The suppression of ovarian function in premenopausal women has been reported to result in amenorrhea in a significant number of patients.
Genitourinary side effects including the suppression of ovarian function in premenopausal women and both reversible and irreversible testicular suppression have been reported.
Fatal outcomes associated with pulmonary fibrosis have been reported.
Respiratory side effects including pulmonary fibrosis and interstitial pneumonitis have been reported.
Dermatologic side effects including , maculopapular rashes, skin rashes, alopecia, and skin hypersensitivity have been reported.
Cardiovascular side effects including cardiac arrest and vasculitis have been reported.
Gastrointestinal side effects including nausea and vomiting, diarrhea, and oral ulceration have been reported infrequently.
Hepatic side effects including toxicity have been reported rarely.
Hypersensitivity reactions have been reported after multiple courses of treatment and have recurred in patients who previously experienced a hypersensitivity reaction.
Hypersensitivity side effects including anaphylaxis have been reported rarely.
Endocrine side effects including two cases of syndrome of inappropriate antidiuretic hormone secretion have been reported following high-dose intravenous melphalan.
Other side effects including a sensation of warmth and/or tingling have been reported.
Renal side effects including temporary significant elevation of the blood urea have been seen in the early stages of therapy in patients with renal damage.Top
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.